Google DeepMind CEO says 2025's the year we start popping pills AI helped invent

Google DeepMind CEO Demis Hassabis anticipates clinical trials for AI-designed drugs by the end of 2025, potentially revolutionizing pharmaceutical development. Isomorphic Labs, DeepMind's spin-off, is using machine learning to accelerate drug discovery, aiming for personalized medicine optimized by AI.

While AI offers potential for significant time and cost savings in drug development, challenges exist in obtaining high-quality training data due to privacy and data-sharing issues. Hassabis emphasizes that AI is not meant to replace scientists, but rather to assist them, as true invention and hypothesis generation still require human expertise.

Companies like Nvidia are also investing in AI for drug discovery, highlighting the growing interest and potential of this technology.